Dublin, Dec. 21, 2020 (GLOBE NEWSWIRE) -- The "Ankylosing Spondylitis - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
Global Ankylosing Spondylitis market accounted for $4.38 billion in 2019 and is expected to reach $9.59 billion by 2027 growing at a CAGR of 10.3% during the forecast period.
Rising prevalence of Ankylosing Spondylitis, growing awareness about diagnostics and treatments for the disease. Additionally, government initiatives and getting better healthcare infrastructure are the major factors propelling the market growth. However, the huge cost of treatment and lack of skilled surgeons and physiotherapists are hampering the market growth.
Ankylosing spondylitis is a chronic inflammatory disease that affects the spine. It is a kind of arthritis, in which spine bones grow or fuse together, causing the spine to turn into rigid. Symptoms of ankylosing spondylitis comprise pain and stiffness from the neck to the lower back, bony fusion, and pain in the ligaments and tendons. These symptomatic changes may be mild or severe, and may lead to a stooped-over posture.
Based on the drugs, the humira segment is going to have a lucrative growth during the forecast period due to it's a prescription medicine used to reduce the signs and symptoms of ankylosing spondylitis in adults. Humira can help to reduce the back pain, stiffness of AS, low cost and high efficiency.
By geography, North America is going to have a lucrative growth during the forecast period due to the more prevalence of the disease and amplified adoption of ankylosing spondylitis treatment options in the region. In addition, technological developments are driving ankylosing spondylitis treatment in this region.
Some of the key players profiled in the Ankylosing Spondylitis Market include Abbvie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eisai, Eli Lilly and Company, F. Hoffmann-La Roche, Janssen Pharmaceuticals, Johnson & Johnson Services, Inc, Merck & Co, Novartis AG, Pfizer, Regeneron Pharmaceuticals, Sanofi, Shanghai Pharmaceuticals and UCB, Inc.
What the report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2018, 2019 2020, 2024, and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends Company Profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Molecule Types Covered:
- Biologics
- Biosimilars
- Small Molecules
Route of Administrations Covered:
- Oral
- Parenteral
Dosage Forms Covered:
- Liquid
- Solid
Drugs Covered:
- Cimzia
- Cosentyx
- Enbrel
- Humira
- Remicade
- Simponi
Drug Types Covered:
- Anti-Inflammatory Drugs
- COX Inhibitors
- Disease-Modifying Anitrheumatic Drugs (DMARDs)
- Immunosuppressive Drugs
- JAK Inhibitors
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Steroids
- TNF Inhibitors
- IL-17 Inhibitors
Treatment Types Covered:
- Medication
- Surgery
- Therapy
Applications Covered:
- Adults
- Juveniles
End Users Covered:
- Hospital
- Care Home
- Clinic
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
For more information about this report visit https://www.researchandmarkets.com/r/mkp72o
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.